No Data
Zhejiang Jiuzhou Pharmaceutical (SHSE:603456) Seems To Use Debt Quite Sensibly
Zhejiang Jiuzhou Pharmaceutical (603456.SH): Dopamine Hydrochloride Injection obtained the pharmaceutical registration certificate.
Zhejiang Jiuzhou Pharmaceutical (603456.SH) announced on October 31st that its holding subsidiary Nanjing Kang Chuanji Medical Technology Co., Ltd. (referred to as "Kang Chuanji Medicine") has received the "Drug Registration Certificate" for Dopamine Hydrochloride Injection issued by the National Medical Products Administration (Acceptance No.: CYHS2301483). Dopamine Hydrochloride Injection is suitable for shock syndrome caused by myocardial infarction, trauma, endotoxin septicemia, heart surgery, renal failure, congestive heart failure with insufficient blood volume correction, especially in shock with oliguria and normal or low peripheral vascular resistance.
Zhejiang Jiuzhou Pharmaceutical Q3 Profit Falls 55%, Revenue Slips 9%
Zhejiang Jiuzhou Pharmaceutical (603456.SH): Passed the on-site inspection by the US FDA.
Zhejiang Jiuzhou Pharmaceutical (603456.SH) announced that the company's Waisa factory area will be shut down from August 19, 2024 to 202...
Zhejiang Jiuzhou Pharmaceutical Co., Ltd. Report for the Third Quarter of 2024
Zhejiang Jiuzhou Pharmaceutical (603456.SH): The net income in the first three quarters was 0.631 billion yuan, a year-on-year decrease of 34.74%.
On October 24, zhejiang jiuzhou pharmaceutical (603456.SH) announced that the company's revenue for the first three quarters was 3.965 billion yuan, a year-on-year decrease of 13.36%; net income attributable to shareholders of the listed company was 0.631 billion yuan, a year-on-year decrease of 34.74%; net income attributable to shareholders of the listed company excluding non-recurring gains and losses was 0.952 billion yuan, a year-on-year decrease of 35.04%; basic earnings per share were 1.09 yuan.
Those Who Invested in Zhejiang Jiuzhou Pharmaceutical (SHSE:603456) Five Years Ago Are up 174%No Data
No Data
